Company |
Date |
Date |
Shares/ |
Price |
Shares |
Lead, other |
Gross |
Post- |
INITIAL OFFERINGS TOTAL: $274.3M | ||||||||
Anaptysbio Inc. (San Diego; ANAB)1 |
9/9/15 |
1/27/17 |
5.75S |
$15 |
19.91 |
Credit Suisse; Stifel Nicolaus; JMP Securities; Wedbush Pacgrow |
$86.25 |
$298.65 |
Jounce Therapeutics Inc. (Cambridge, Mass.; JNCE)2 |
12/30/16 |
1/30/17 |
6.365S |
$16 |
31.17 |
J.P. Morgan; Cowen and Co.; Wells Fargo Securities; Robert W. Baird |
$101.84 |
$498.72 |
Obseva SA (Geneva; OBSV)3 |
10/14/16 |
1/27/17 |
6.45S |
$15 |
29.63 |
Credit Suisse Securities; Jefferies; Leerink Partners |
$86.25 |
$444.45 |
|
Number of IPOs in January: 3 Average value of January IPOs: $91.43M Number of IPOs in 2017: 3 Total raised in IPOs in 2017: $274.3M Average value of IPOs in 2017: $91.43M | ||||||||
FOLLOW-ON OFFERINGS TOTAL: $873.36M | ||||||||
Affimed NV (Heidelberg, Germany; AFMD)4 |
10/23/15 |
1/23/17 |
10S |
$1.80 |
43.26 |
BMO Capital Markets; Wells Fargo Securities; Trout Capital |
$18 |
$77.87 |
Athersys Inc. (Cleveland; ATHX)5 |
3/27/14 |
1/30/17 |
19.8S |
$1.01 |
105.6 |
William Blair; Needham & Co. |
$20 |
$106.66 |
Cascadian Therapeutics Inc. (Seattle; CASC)6 |
1/7/15 |
1/25/17 |
23.2S and 0.0018S of series E preferred |
$3.30 |
45.7 |
Cowen and Co.; Barclays Capitals; Raymond James & Associates; BTIG |
$82.5 |
150.81 |
Clovis Oncology Inc. (Boulder, Colo.; CLVS)7 |
1/3/17 |
1/4/17 |
5.75S |
$41.00 |
44.3 |
J.P. Morgan Securities; BofA Merrill Lynch; Stifel; Suntrust Robinson Humphrey |
$235.5 |
$1,816.3 |
Heron Therapeutics Inc. (San Diego; HRTX)8 |
7/29/16 |
1/19/17 |
14.15S |
$12.20 |
53.31 |
BofA Merrill Lynch; Cowen and Co.; Leerink Partners; Cantor Fitzgerald; JMP Securities; Lifesci Capital; Noble Capital Markets; Aegis Capital; Lake Street Capital Markets |
$150.06 |
$650.38 |
Loxo Oncology Inc. (Stamford, Conn.; LOXO)9 |
11/2/16 |
1/12/17 |
4.45S |
$31.00 |
26.13 |
Morgan Stanley; Citigroup; Cowen and Co.; Stifel |
$138 |
$810.03 |
Mirati Therapeutics Inc. (San Diego; MRTX)10 |
11/20/15 |
1/13/17 |
5S and W |
$5.60 |
24.9 |
Leerink Partners |
$68.7 |
$139.44 |
Ocular Therapeutix Inc. (Bedford, Mass.; OCUL) |
4/28/16 |
1/25/17 |
3.6S |
$7 |
28.77 |
Cantor Fitzgerald |
$25.2 |
201.39 |
Rigel Pharmaceuticals Inc. (South San Francisco; RIGL)11 |
7/13/15 |
1/31/17 |
20S |
$2.00 |
118.9 |
Jefferies; Piper Jaffray; BMO Capital Markets; H.C. Wainwright |
$40 |
$237.8 |
Stemline Therapeutics Inc. (New York; STML)12 |
2/12/14 |
1/23/17 |
4.5S |
$10.00 |
23.65 |
Jefferies; Cowen and Co.; Ladenburg Thalmann; H.C. Wainwright; Roth Capital Partners; Joseph Gunnar; Aegis Capital |
$45 |
$236.5 |
Zynerba Pharmaceuticals Inc. (Devon, Pa.; ZYNE)13 |
9/12/16 |
1/20/17 |
2.8S |
$18.00 |
12.8 |
Jefferies; Piper Jaffray; Cantor Fitzgerald; Oppenheimer; Roth Capital Partners |
$50.4 |
$230.4 |
|
Number of follow-on offerings in January: 11 Average value of January follow-ons: $79.4M Number of follow-on offerings in 2017: 11 Total raised in follow-ons in 2017: $873.36M Average value of follow-ons in 2017: $79.4M | ||||||||
|
Notes # Unless otherwise indicated, shares are traded on the Nasdaq exchange. @ This column reflects the shares outstanding following the offering, when disclosed. % Market capitalization is calculated based on the offering price. Currency conversions are based on exchange rates at the time of the deal. This chart includes only biotech companies that develop therapeutics. 1 Includes Anaptysbio's overallotment option: 750,000 shares. 2 Jounce's overallotment option: 954,750 shares. 3 Obseva's overallotment option: 967,500 shares. 4 Affimed's overallotment option: 1.5M shares. 5 Athersys' overallotment option: 2.97M shares. 6 Cascadian's overallotment option: 3.5M shares. 7 Includes Clovis' overallotment option: 750,000 shares. 8 Includes Heron's overallotment option: 1.845M shares. 9 Includes Loxo's overallotment option: 580,500 shares. 10 Includes Mirati's overallotment option: 652,526 shares. Mirati also sold to funds affiliated with Boxer Capital LLC pre-funded warrants to purchase up to 7.25M shares at $5.599 per warrant. 11 Rigel's overallotment option: 3M shares. 12 Stemline's overallotment option: 675,000 shares. 13 Zynerba's overallotment option: 420,000 shares. | ||||||||
